Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A.
Hemophilia A
IL10
TNF a
factor II
factor V
inhibitor
polymorphism.
Journal
Cardiovascular & hematological disorders drug targets
ISSN: 2212-4063
Titre abrégé: Cardiovasc Hematol Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269160
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
05
2018
revised:
28
12
2018
accepted:
16
01
2019
pubmed:
8
2
2019
medline:
5
8
2020
entrez:
8
2
2019
Statut:
ppublish
Résumé
About one-fourth of patients with hemophilia A (HA) develop alloantibodies against factor (F) VIII, as the main treatment challenge. Here, we assessed the relationship between interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α), FII and FV polymorphisms and risk of inhibitor formation in patients with severe HA. We divided 39 patients with severe HA in two groups of case (n: 19) and control (n: 20). Genotyping was performed by multiplex amplification tetra arms refractory mutation systempolymerase chain reaction (ARMS-PCR) and PCR-restriction fragment-length polymorphism (PCR-RFLP). TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor development in codominant and dominant inheritance pattern. Moreover, TNFα rs1800629 A allele, decrease the risk of inhibitor formation, while IL10 rs1800896 A>G, FV rs6025 G>A, and FII rs1799963 G>A polymorphisms were not associated with risk of inhibitor development. It seems that TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor formation in Iranian patients with HA.
Sections du résumé
BACKGROUND
About one-fourth of patients with hemophilia A (HA) develop alloantibodies against factor (F) VIII, as the main treatment challenge. Here, we assessed the relationship between interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α), FII and FV polymorphisms and risk of inhibitor formation in patients with severe HA.
METHODS
We divided 39 patients with severe HA in two groups of case (n: 19) and control (n: 20). Genotyping was performed by multiplex amplification tetra arms refractory mutation systempolymerase chain reaction (ARMS-PCR) and PCR-restriction fragment-length polymorphism (PCR-RFLP).
RESULTS
TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor development in codominant and dominant inheritance pattern. Moreover, TNFα rs1800629 A allele, decrease the risk of inhibitor formation, while IL10 rs1800896 A>G, FV rs6025 G>A, and FII rs1799963 G>A polymorphisms were not associated with risk of inhibitor development.
CONCLUSION
It seems that TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor formation in Iranian patients with HA.
Identifiants
pubmed: 30727925
pii: CHDDT-EPUB-96413
doi: 10.2174/1871529X19666190206152315
doi:
Substances chimiques
IL10 protein, human
0
Isoantibodies
0
Tumor Necrosis Factor-alpha
0
Interleukin-10
130068-27-8
Factor V
9001-24-5
Prothrombin
9001-26-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
228-232Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.